Exelixis, Storm to collaborate on cancer treatments

By The Science Advisory Board staff writers

October 14, 2021 -- Exelixis and Storm Therapeutics have entered into an exclusive collaboration and license agreement to discover and develop new drug leads to treat cancer.

Under the terms of the agreement, Exelixis will pay Storm an upfront fee of $17 million to license two of Storm's discovery programs targeting RNA-modifying enzymes. Proceeds will also help fund discovery research activities conducted or managed by Storm.

The collaboration will focus initially on a protein called RNA-specific adenosine deaminase 1 (ADAR1) to deliver small-molecule clinical candidate compounds discovered using Storm's proprietary RNA-modifying enzyme drug discovery platform.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.